{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:02:45Z","timestamp":1787846565799,"version":"build-2784847793"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Hepatotoxic effects, including hyperbilirubinemia and elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, are common during all phases of therapy and are linked to several chemotherapeutic agents, including asparaginase, mercaptopurine, and methotrexate.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine which genetic variants were associated with hyperbilirubinemia and elevated ALT and AST levels in children, adolescents, and young adults treated for ALL.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective analysis of a multiethnic genome-wide association study was conducted between January 1, 2019, and April 15, 2022, including patients treated as part of Children\u2019s Oncology Group (COG) trials with centers in the United States, Canada, and Australia, which accrued data from December 29, 2003, to January 21, 2011 (AALL0232), and from January 22, 2007, to July 24, 2014 (AALL0434). Germline genotypes were interrogated using genome-wide arrays and imputed using a National Institutes of Health TOPMed Imputation server. Mixed-effects logistic regressions were used to account for multiple episodes for an individual patient. Genotype \u00d7 treatment phase interaction was tested to uncover phase-specific genetic risk factors.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Total duration of multiagent protocol chemotherapy ranging from 2.5 to 3.5 years.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcomes were National Cancer Institute Common Terminology Criteria for Adverse Events (version 4) hyperbilirubinemia of grade 3 or higher and elevated liver ALT and AST levels.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 3557 participants were included in the analysis (2179 [61.3%] male; median age, 11.1 [range, 1-30] years). Among 576 known variants associated with these liver function test results in the general population, UGT1A1<\/jats:italic> variant rs887829<\/jats:ext-link> and PNPLA3<\/jats:italic> variant rs738409<\/jats:ext-link> were associated with increased risk of hyperbilirubinemia (odds ratio [OR], 2.18 [95% CI, 1.89-2.53]; P<\/jats:italic>\u2009=\u20096.7 \u00d7 10\u221227<\/jats:sup>) and ALT and AST levels (OR, 1.27 [95% CI, 1.15-1.40]; P<\/jats:italic>\u2009=\u20093.7 \u00d7 10\u22127<\/jats:sup>), respectively, during treatment for ALL. Corresponding polygenic risk scores were associated with hepatotoxic effects across all therapy phases and were largely driven by UGT1A1<\/jats:italic> and PNPLA3<\/jats:italic> variants. Genome-wide association analysis revealed an age-specific variant near the CPT1A<\/jats:italic> gene that was only associated with elevated ALT and AST levels among patients younger than 10 years (OR, 1.28 [95% CI, 1.18-1.39]; P<\/jats:italic>\u2009=\u20098.7 \u00d7 10\u221210<\/jats:sup>).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>These results suggest a strong genetic basis for interpatient variability in hyperbilirubinemia and aminotransferase level elevations during leukemia chemotherapy.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.48803","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T16:32:31Z","timestamp":1672331551000},"page":"e2248803","source":"Crossref","is-referenced-by-count":24,"title":["Association of Inherited Genetic Factors With Drug-Induced Hepatic Damage Among Children With Acute Lymphoblastic Leukemia"],"prefix":"10.1001","volume":"5","author":[{"given":"Wenjian","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Sciences, St Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth E.","family":"Karol","sequence":"additional","affiliation":[{"name":"Department of Oncology, St Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keito","family":"Hoshitsuki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Sciences, St Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Sciences, St Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Larsen","sequence":"additional","affiliation":[{"name":"Maine Children\u2019s Cancer Program, Scarborough"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Winick","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Carroll","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mignon L.","family":"Loh","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Hospital, the Ben Town Center for Childhood Cancer Research, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Raetz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, New York University Grossman School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Hunger","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children\u2019s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart S.","family":"Winter","sequence":"additional","affiliation":[{"name":"Cancer and Blood Disorders Program, Children\u2019s Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly P.","family":"Dunsmore","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Virginia, Charlottesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Devidas","sequence":"additional","affiliation":[{"name":"Department of Global Pediatric Medicine, St Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary V.","family":"Relling","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Sciences, St Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun J.","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Sciences, St Jude Children\u2019s Research Hospital, Memphis, Tennessee"},{"name":"Department of Oncology, St Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"issue":"14","key":"zoi221380r1","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children\u2019s Oncology Group.","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi221380r2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1182\/blood.2020007702","article-title":"Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia.","volume":"137","author":"Teachey","year":"2021","journal-title":"Blood"},{"issue":"10","key":"zoi221380r3","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1182\/blood-2006-10-054528","article-title":"Ancestry and pharmacogenetics of antileukemic drug toxicity.","volume":"109","author":"Kishi","year":"2007","journal-title":"Blood"},{"issue":"1","key":"zoi221380r4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/cpt.v102.1","article-title":"Genome-wide study links PNPLA3 variant with elevated hepatic transaminase after acute lymphoblastic leukemia therapy.","volume":"102","author":"Liu","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"14","key":"zoi221380r5","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1093\/hmg\/ddp202","article-title":"Genome-wide association meta-analysis for total serum bilirubin levels.","volume":"18","author":"Johnson","year":"2009","journal-title":"Hum Mol Genet"},{"issue":"12","key":"zoi221380r6","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"issue":"2","key":"zoi221380r7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41588-020-00757-z","article-title":"Genetics of 35 blood and urine biomarkers in the UK Biobank.","volume":"53","author":"Sinnott-Armstrong","year":"2021","journal-title":"Nat Genet"},{"issue":"28","key":"zoi221380r11","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children\u2019s Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia.","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J Clin Oncol"},{"issue":"20","key":"zoi221380r12","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","article-title":"Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children\u2019s Oncology Group Study AALL0232.","volume":"34","author":"Larsen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"15","key":"zoi221380r13","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1182\/blood-2015-05-643601","article-title":"Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia.","volume":"126","author":"Karol","year":"2015","journal-title":"Blood"},{"issue":"12","key":"zoi221380r14","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1093\/jnci\/djz043","article-title":"Genome-wide association study of susceptibility loci for T-cell acute lymphoblastic leukemia in children.","volume":"111","author":"Qian","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"zoi221380r16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/cpt.v107.1","article-title":"The Clinical Pharmacogenetics Implementation Consortium: 10 years later.","volume":"107","author":"Relling","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"zoi221380r18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1177\/1078155217710714","article-title":"Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: a case report and review of the literature.","volume":"24","author":"Blackman","year":"2018","journal-title":"J Oncol Pharm Pract"},{"issue":"21","key":"zoi221380r19","doi-asserted-by":"publisher","first-page":"7551","DOI":"10.1002\/cam4.v10.21","article-title":"Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia.","volume":"10","author":"Schulte","year":"2021","journal-title":"Cancer Med"},{"issue":"13","key":"zoi221380r20","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1080\/10428194.2020.1805108","article-title":"Levocarnitine for pegasparaginase-induced hepatotoxicity in acute lymphoblastic leukemia.","volume":"61","author":"Trang","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"zoi221380r21","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1080\/10428194.2019.1571198","article-title":"L-carnitine does not ameliorate asparaginase-associated hepatotoxicity in a C57BL6 mouse model.","volume":"60","author":"Liu","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"zoi221380r22","doi-asserted-by":"publisher","first-page":"17463","DOI":"10.1016\/S0021-9258(19)85357-7","article-title":"The human S mu bp-2, a DNA-binding protein specific to the single-stranded guanine-rich sequence related to the immunoglobulin mu chain switch region.","volume":"268","author":"Fukita","year":"1993","journal-title":"J Biol Chem"},{"issue":"5","key":"zoi221380r23","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/ndt\/gfp661","article-title":"Variation in IGHMBP2 is not associated with IgA nephropathy in independent studies of UK Caucasian and Chinese Han patients.","volume":"25","author":"Lou","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"zoi221380r24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s10038-004-0214-8","article-title":"Association of a single-nucleotide polymorphism in the immunoglobulin mu-binding protein 2 gene with immunoglobulin A nephropathy.","volume":"50","author":"Ohtsubo","year":"2005","journal-title":"J Hum Genet"},{"issue":"3","key":"zoi221380r25","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/cpt.2241","article-title":"Class II human leukocyte antigen variants associate with risk of pegaspargase hypersensitivity.","volume":"110","author":"Liu","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"1-2","key":"zoi221380r26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2007.11.005","article-title":"Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes.","volume":"354","author":"Ishida","year":"2008","journal-title":"Int J Pharm"},{"issue":"25","key":"zoi221380r27","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood.2020006214","article-title":"Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatment.","volume":"136","author":"Liu","year":"2020","journal-title":"Blood"},{"issue":"2","key":"zoi221380r28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/(SICI)1096-911X(199602)26:2<85::AID-MPO3>3.0.CO;2-Q","article-title":"Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristics.","volume":"26","author":"Berkovitch","year":"1996","journal-title":"Med Pediatr Oncol"},{"issue":"8","key":"zoi221380r29","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1200\/JCO.2001.19.8.2293","article-title":"Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.","volume":"19","author":"Evans","year":"2001","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi221380r30","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1001\/jamaoncol.2021.6826","article-title":"Association of genetic ancestry with the molecular subtypes and prognosis of childhood acute lymphoblastic leukemia.","volume":"8","author":"Lee","year":"2022","journal-title":"JAMA Oncol"},{"issue":"8","key":"zoi221380r31","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/hep4.1382","article-title":"Genetic polymorphisms implicated in nonalcoholic liver disease or selected other disorders have no influence on drug-induced liver injury.","volume":"3","author":"Bonkovsky","year":"2019","journal-title":"Hepatol Commun"},{"key":"zoi221380r8","unstructured":"The NHGRI-EBI Catalog of human genome-wide association studies. Accessed September 30, 2021. https:\/\/www.ebi.ac.uk\/gwas\/"},{"key":"zoi221380r9","unstructured":"ClinicalTrials.gov. Dexamethasone compared with prednisone during induction therapy and methotrexate with or without leucovorin during maintenance therapy in treating patients with newly diagnosed high-risk acute lymphoblastic leukemia. ClinicalTrials.gov identifier: NCT00075725. Updated April 27, 2021. Accessed November 18, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00075725"},{"key":"zoi221380r10","unstructured":"ClinicalTrials.gov. Combination chemotherapy in treating young patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. ClinicalTrials.gov identifier: NCT00408005. Updated October 12, 2022. Accessed November 18, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00408005"},{"key":"zoi221380r15","unstructured":"Clinical Pharmacogenetics Implementation Consortium. Accessed September 30, 2021. https:\/\/cpicpgx.org\/"},{"key":"zoi221380r17","unstructured":"Center for Statistical Genetics. Stouffer method for meta-analysis. Updated April 5, 2010. Accessed November 15, 2020. https:\/\/genome.sph.umich.edu\/wiki\/Stouffer_Method_for_Meta-Analysis"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2799970\/yang_2022_oi_221380_1671211110.16834.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T16:32:38Z","timestamp":1672331558000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2799970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.48803","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]}}}